Showing posts with label alzheimer. Show all posts
Showing posts with label alzheimer. Show all posts

Jul 5, 2011

Could a Diet Help Prevent Alzheimer's?

The low-fat, low-glycemic diet often promoted for general health and well-being may lower the risk of developing Alzheimer's disease if adopted early in life, researchers say.
But starting such an eating plan after symptoms surface doesn't seem to help prevent deterioration of brain function, according to new research published online June 13 in Archives of Neurology."
This is not the first time this concept has emerged, that things you do in midlife or earlier on may have effects later on," said Dr. Marc L. Gordon, chief of neurology at Zucker Hillside Hospital and an Alzheimer's researcher at the Feinstein Institute for Medical Research in Manhasset, N.Y." For example, we know that midlife obesity is associated epidemiologically with a higher risk of late-life dementia," he continued. "Whether that's causal or an effect of the disease is open to speculation, but it suggests that there may be periods of vulnerability that are different in different times in the life span."
Although numerous studies have probed connections between lifestyle factors and cognitive ability, no solid proof yet exists that diet (or much else) can prevent Alzheimer's, the most common form of dementia among the elderly. A low-glycemic diet, which focuses on eating fruits and vegetables, whole grains and lean meats, avoids spikes in blood sugar and is said to promote feelings of fullness.
A U.S. National Institutes of Health conference convened last spring concluded that, for now, older age is the leading known risk factor for Alzheimer's disease. A gene variation is also tied to increased risk for the brain disorder, the NIH review said. Experts at the conference stressed that the general public should still focus on avoiding behaviors already linked to other chronic diseases.This new study looked at the effect of different diets on biomarkers associated with Alzheimer's, such as blood sugar levels, cholesterol and blood lipid levels. The researchers also tested memory after participants followed the assigned diets. Twenty healthy adults and 29 with mild memory problems that could be predictive of Alzheimer's followed either a high-fat, high simple-carbohydrate diet ("HIGH" diet) or a diet lower in fat and simple carbohydrates ("LOW" diet). After four weeks, healthy participants on the LOW diet had changes in biomarkers, including insulin and lipid levels in the blood, which were moving away from those normally associated with dementia. In participants with mild cognitive impairment, this diet had the opposite effect.Commenting on the study, Dr. Suzanne de la Monte, professor of neurosurgery and pathology at Brown University and Rhode Island Hospital in Providence, said it remains to be seen if the changes noted in this study actually translate, over the longer term, into differences in risk for developing Alzheimer's disease.
The bottom line, though, is the same as it's been for eons: A healthy diet lowers your risk of type 2 diabetes, heart disease, cancer and maybe even Alzheimer's.That means staying away as much as possible from processed foods, de la Monte advised.A second study, in the same issue of the journal, also looked at biomarkers and found that different levels were associated with different measures of cognitive function associated with Alzheimer's disease.
This finding could help improve diagnosis of Alzheimer's, which now relies mostly on clinical observation.
SOURCES: Marc L. Gordon, M.D., chief, neurology, Zucker Hillside Hospital and Alzheimer's research, the Feinstein Institute for Medical Research, Manhasset, N.Y.; Suzanne de la Monte, M.D., professor of neurosurgery and pathology, Brown University and Rhode Island Hospital, Providence, R.I.; June 13, 2011, Archives of Neurology, online

Oct 30, 2009

Learning of Risk of Alzheimer’s Seems to Do No Harm

A genetic test that can find an increased risk of Alzheimer’s diseasedoes no psychological harm to people who take it, even if they test positive for a risky gene, a new study finds.

The results challenge views long held by the medical establishment, which has discouraged people from being tested, arguing that the test is not definitive, that it may needlessly frighten people into thinking a terrible disease is hanging over them and that testing is pointless anyway because there is no way to cure or prevent the dementiacaused by Alzheimer’s.

Follow the lonk and read the full article.

Oct 25, 2009

Smart Genetics Shuts Its Doors

Direct-to-consumer genetic testing company, Smart Genetics, has gone out of business.
The two-year-old company sold HIV Mirror and Alzheimer’s Mirror, DNA tests for HIV progression to AIDS and Alzheimer’s risk respectively.I first wrote about HIVmirror in June 2007. Aimed at HIV+ individuals, the test analyzes the CCR5 Delta32 and CCR2-64I genetic variants previously shown to slow the progression of HIV infection to AIDS.
Alzheimer’s Mirror examined the APOE gene.CEO and co-founder Julian Awad first received funding for the company while at the Wharton School of Business. He was later profiled by CBS News for Alzheimer’s Mirror and found that his own personal lifetime risk of Alzheimer’s disease is about 9 to 10 percent compared to 15% for the general population.
Ironically, he was also mentioned in a Wharton article from 2007 – Can Anyone Make Sense — or Money — Out of Personal DNA Testing?
Apparently not.

by Dr. Hsien-Hsien Lei

Jul 21, 2009

ALZHEIMER: L’IMPORTANZA DELLA PREVENZIONE

Scegliere di sottoporsi a un test genetico rappresenta una presa di coscienza verso se stessi, un’opportunità per migliorare il proprio stato di salute e la qualità di vita. “Chi decide di eseguire un test genetico per la valutazione del proprio rischio di sviluppare la malattia di Alzheimer” dichiara il dott. Giuseppe Di Fede, “sta compiendo un passo in direzione della prevenzione. Vivere a lungo è infatti un’opportunità vuota di senso se alla quantità di anni non si associa la possibilità di vivere una vita di qualità, in autonomia fisica e psichica. ” Chi deve sottoporsi al test? Il test genetico si rivolge ad un segmento di popolazione di età compresa tra i 35 anni e i 75 anni. La vera prevenzione si realizza tra i 40 ed i 65 anni, periodo in cui se è presente il rischio genetico di sviluppare la patologia, è alta la possibilità di bloccarne lo sviluppo, attuando protocolli e percorsi diagnostici, terapeutici e preventivi. “Tra i 50 e i 65 anni è ancora possibile instaurare una terapia medica adeguata per rallentare la manifestazione della patologia, ma, in questo caso, non si può parlare di prevenzione ma di diagnosi precoce di Demenza o pre-Demenza. ” Il test genetico ha una indicazione mirata verso quelle persone che hanno una familiarità per il Morbo di Alzheimer, con parenti stretti, padre, nonno, cugini, zii, ma si rivolge anche a tutti coloro che vogliono prendere coscienza del proprio stato di salute per poterlo mantenere o migliorarlo. “Eseguire un test genetico è una scelta libera e personale” afferma il dott. Di Fede “che in genere, però, vede coinvolte sia la persona che si sottopone al test, sia la famiglia. Infatti, soprattutto in caso di referto che indichi rischio elevato a sviluppare la malattia, la famiglia acquista un ruolo importante di sostegno nelle fasi di follow-up e di coinvolgimento dell’adottare stili di vita preventivi. La partecipazione è spesso così importante che tutti i famigliari di un soggetto ad elevato rischio iniziano percorsi di prevenzione, favorendo quindi lo svilupparsi di una cultura di promozione della salute”. Il referto personalizzato contiene una determinazione del profilo di rischio pro infiammatorio associato al Decadimento Cognitivo e alla Demenza Senile, espresso in rischio Basso, Medio, Alto. Il referto è semplice da comprendere, non necessita di un genetista per la sua lettura, ma di un medico che conosca i passi e i protocolli da mettere in atto, quali esami richiedere e quali percorsi preventivi attuare. “Non si deve pensare che il test genetico crei malati o situazioni di vita da malati. Anche nei casi di rischio medio o alto gli esami diagnostici si effettuano una volta l’anno, proprio come sottoporsi ad un normale check up”. Gli esami che rientrano nel protocollo annuale sono: - la Tomografia Computerizzata dell’encefalo, - valutazione neurocognitiva, - determinazione dei fattori favorenti l’infiammazione. Ogni valutazione viene accompagnata da un’accurata anamnesi per determinare la presenza o meno di demenza o decadimento cognitivo nei familiari, controllo dello stile di vita, dell’attività fisica e dell’alimentazione, e se necessario vengono consigliati anche controlli per la determinazione di eventuali incompatibilità alimentari.

Jun 27, 2009

Genetic Testing for People

Healthy people who have family members with Alzheimer's disease may want to pursue genetic testing to find out if they are at risk. However, genetic testing for Alzheimer's disease is only available under very specific circumstances. Because the one gene for which genetic testing is available tends to cause an early onset form of the disease, genetic testing is only appropriate for people who's family members developed Alzheimer's at an early age. In some cases, genetic testing can also be used to confirm a diagnosis of Alzheimer's disease in people who already show symptoms.

Testing for Predictive Genes
There are three rare genetic syndromes that cause people to develop Alzheimer's disease at an early age, typically before age 60. These syndromes are caused by mutations in single genes called APP, PS1, and PS2. If one of your parents has a mutation in any of these genes, you have a 50 percent chance of inheriting the mutation and developing Alzheimer's yourself. This pattern of inhertance is called autosomal dominant. By examining your family's medical history, a genetic counselor can often assess your risk of carrying one of these mutations, and can determine whether genetic testing is appropriate for you.

Drawbacks. 
If you do have a family history of early onset Alzheimer's disease, genetic testing may still not be able to detect the mutation that's causing your family's disease.Clinical genetic testing is currently only available for one of the three known genes – PS1. Testing for the other two genes is available on a research basis only.
The three genes for which genetic testing is available only account for about half of the families with Alzheimer's – or about five percent of all cases. Therefore, there must be other genes that have not yet been identified.The 

Importance of Testing the Right Family Member
Even if you decide to pursue genetic testing, you may not be the best person in your family to be tested. This is because testing should begin with the family member who is most likely to have a mutation — and that generally means someone who's already been diagnosed with Alzheimer's. The research lab will sequence this person's entire PS1 gene. If they find a mutation, then other family members can be screened for this same mutation. (Screening for a known mutation is generally faster and less expensive than sequencing the entire gene.) If the lab does not find a mutation in a family member with Alzheimer's disease, then your family's Alzheimer's is not caused by a mutation in the PS1 gene and genetic testing will not be helpful in determining your risk.

Not All Cases of Alzheimer's Disease Result From a Mutated Gene
When looking at your family history of Alzheimer's disease, it is important to keep in mind that Alzheimer's can develop in people who have not inherited a mutated PS1, PS2, or APP gene. In families who have identified a mutation in PS1, even family members who did not inherit this mutation are at risk of developing the disease — the same risk as people in the general population. For this reason, you should keep in mind the age of onset for a family member who you choose to have tested. If they didn't develop the disease until late in life, they are probably not the best person to be tested for a mutation. You and your relatives should also be aware that if you test negative for a mutation that runs in your family, it does not mean that you won't develop the disease, only that you aren't at higher risk than the general population.

Testing for Susceptibility Genes.
Mutations in APP, PS1, or PS2 all virtually guarantee that a person will develop Alzheimer's disease. However, there is a fourth gene – called APOE – that is also involved in determining Alzheimer's risk. The APOE gene comes in three forms, called e2, e3, and e4. Having the e4 version puts people at higher risk of Alzheimer's disease, but does not ensure that they will develop the disease. Because testing for e4 cannot predict who will get the disease, many medical ethicists and geneticists have recommended against testing for APOE in healthy people.The rationale for not testing for APOE is that over half the people who carry e4 will not develop Alzheimer's and many people who don't carry e4 will still go on to develop the disease; therefore, genetic testing is not very useful. In fact, genetic testing for this gene is only currently available to help confirm doctor's diagnoses of Alzheimer's, and a doctor is required to sign a form that says the patient has dementia before the test can be performed.

The Future of Testing for Susceptibility Genes.
If you do not qualify for standard genetic testing for the APOE e4 variation, and you still wish to be tested, genetic testing for APOE and the other Alzheimer's genes is sometimes available as part of ongoing research studies. A medical geneticist or genetic counselor may be able to help you find such studies.Furthermore, ethicist have suggested that testing for susceptibility to Alzheimer's would be much more acceptable if there were a way to prevent the disease. Thus, as researchers make strides towards preventing and treating Alzheimer's, genetic testing for APOE e4 (and other genes for Alzheimer's susceptibility that might be discovered in the future) are likely to be more widely available.Issues to Consider
Considering genetic testing for Alzheimer's is complicated by the fact that even if you test positive for a mutation, there is no way to prevent the disease or treat it once it develops. Despite this drawback, some people decide to pursue genetic testing because it helps them plan for the future and relieves anxiety. However, other people find that they simply don't want to know whether they are going to get a disease that they cannot prevent.
Studies in Huntington's disease – which is similar to Alzheimers in that it is autosomal dominant and currently has no prevention or treatment – gives some insight into how people make decisions about genetic testing for these types of diseases. These studies have found that only about 15 to 20 percent of those at risk actually seek out and go through with getting a genetic test.
Meeting with a genetic counselor can help you understand both whether you are eligible for genetic testing and what risks and benefits there are to testing. In addition to meeting with a genetic counselor, it can be helpful to discuss the decision with family members, religious advisors, and possibly other people who have faced the same decision, such as through a support group. Even if you choose not to have a genetic test for Alzheimer's, you can make legal and financial plans to protect your family's future. The Alzheimer's Association has information to help you with those steps. It is also important to remember that deciding not to be tested is not a permanent decision; you can change your mind at any time as more researchers uncover methods for treatment and prevention.

Jun 1, 2009

Alzheimer più probabile per i depressi.



Secondo uno studio olandese e uno americano, chi ha sofferto di depressione ha due volte e mezzo più probabilità degli altri di contrarre il morbo.

Tuttavia, i ricercatori olandesi, hanno precisato che sono necessarie altre ricerche per comprendere appieno il legame tra la malattia D Alzheimer e la depressione: “Non sappiamo ancora se la depressione contribuisce allo sviluppo dell’Alzheimer – hanno confessato – o se un altro fattore sconosciuto causi sia la depressione che la demenza senile.” Dal canto loro, gli scienziati americani sottolineano comunque che la depressione è un fattore di rischio per l’Alzheimer ma non un sintomo precoce del morbo.
In altre parole, non tutti i depressi si ammaleranno. Insomma, ancorché non definitivi, i risultati aiuteranno comunque a capire di più i meccanismi del morbo e creare nuove prospettive di ricerca.

Articolo pubblicato sul quotidiano “City” in data 9 Aprile 2008.

Apr 17, 2009

un test per scoprire l'alzheimer prima che colpisca

(da Repubblica)

Un semplice esame del sangue per scoprire in anticipo se piccoli disturbi di memoria sono segni di un normale processo di invecchiamento o si trasformeranno, invece, in qualcosa di più grave come l'Alzheimer. Uno degli aspetti più strazianti della malattia è proprio la difficoltà di individuarne per tempo e con certezza i primi segnali. Ora, grazie a una nuova ricerca scientifica, l'obiettivo sembra più vicino. 

In uno studio pubblicato su Nature Medicine un gruppo di ricercatori dell'università americana di Stanford ha identificato un gruppo di 18 proteine usate dalle cellule per comunicare tra di loro e che permettono di predire con un'accuratezza del 90 per cento se una persona svilupperà o meno la malattia. 

Esiste una connessione fra i cambiamenti che si verificano nel cervello di chi soffre di Alzheimer e il modo in cui le cellule comunicano fra di loro. Per i ricercatori, guidati dal professor Tony Wyss-Coral, il test che coglie le modificazioni in queste proteine è in grado di determinare se la malattia si svilupperà nei successivi due-sei anni, in anticipo quindi rispetto alla comparsa dei sintomi più significativi.  

I ricercatori hanno analizzato 259 campioni di sangue da diversi pazienti: alcuni colpiti dai primi sintomi della malattia, altri già a stadi conclamati e avanzati, altri ancora che non presentavano alcun sintomo. E, partendo da un gruppo di 120 proteine note per la loro attività di comunicazione fra le cellule, ne hanno individuate 18 chiave, specifiche, che sono espresse in concentrazioni diverse nelle persone malate di Alzheimer. Queste proteine sono anche implicate nella produzione di nuove cellule del sangue, nei processi immunitari e nella morte delle cellule al termine del loro ciclo naturale. L'ipotesi è che ci sia qualcosa di errato nell'informazione contenuta nel DNA e che porta alla produzione di determinate cellule del sangue che svolgono un ruolo importante nell'eliminare quei depositi che si accumulano nel cervello delle persone malate di Alzheimer. La diagnosi precoce rappresenta un'arma in più per combattere l'Alzheimer.